Comparison
MGF (Mechano Growth Factor) vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
2023788-19-2
Molecular weight
2867.2 g/mol
4813 g/mol
Half-life
0.1 h
116 h
Sequence
YQPPSTNKNTKSQRRKGSTFEERKYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
3
of which in humans
0
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2